A Dose-response Study of AMG 162 (Denosumab) in Patients with Rheumatoid Arthritis on Methotrexate (MTX) to Validate Inhibitory Effect on Bone Erosion (Phase II)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Jan 2019 Results of a sub-group analysis (n=340) assessing bone erosion progression among RA patients in risk factor subgroups published in the Rheumatology
08 Nov 2017 Results of sub-group analysis (n=909) assessing the effect of denosumab upon progression of the joint destruction in rheumatoid arthritis patients using pooled data from two trials (DRIVE and DESIRABLE), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
19 Nov 2015 Results published in the Annals of the Rheumatic Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com